Back to top
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Novartis AG (NVS) - free report >>
Pacira BioSciences, Inc. (PCRX) - free report >>
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Novartis AG (NVS) - free report >>
Pacira BioSciences, Inc. (PCRX) - free report >>
Image: Bigstock
Xencor (XNCR) Doses First Patient in Myeloid Leukemia Trial
Xencor, Inc. (XNCR - Free Report) announced that the first patient has been dosed in a phase I trial on lead candidate XmAb14045 for the treatment of acute myeloid leukemia (AML) and other CD123-expressing hematologic malignancies.
The trial will evaluate the safety and tolerability of weekly intravenous administration of XmAb14045 and determine the maximally tolerated dose/dosing schedule. The trial will enrol approximately 60 patients with AML or other CD123-expressing hematologic malignancies who will receive XmAb14045.
The candidate showed efficacy and potent depletion of target cells in primate studies from a well-tolerated single IV dose.
We note that XmAb14045 is Xencor's lead bispecific candidate. The company earlier inked a collaboration agreement with Swiss major Novartis (NVS - Free Report) .
As per the agreement terms, the companies will collaborate to develop and commercialize two pipeline candidates – XmAb14045 and XmAb13676 (to enter clinical development for B-cell malignancies in 2016). The companies will share the cost of the development of the candidates. While Xencor will retain commercialization rights in the U.S., Novartis will own the marketing rights in the rest of the world.
Additionally, Novartis will receive worldwide rights to Xencor's bispecific technology to develop and commercialize four targets. These targets will be selected by Novartis and Xencor may elect to co-detail one of these targets in the U.S. Novartis will also receive a worldwide non-exclusive license to use Xencor's XmAb Fc technologies in up to 10 molecules.Xencor currently carries a Zacks Rank #3 (Hold). A couple of well placed stocks in the healthcare stocks include Pacira Pharmaceuticals (PCRX - Free Report) and ANI Pharmaceuticals (ANIP - Free Report) . Both these stocks sport a Zacks Rank #1 (Strong Buy).
You can see the complete list of today’s Zacks #1 Rank stocks here
Confidential from Zacks
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>